This bill inserts a new statutory section into the Public Health Service Act to make the Advisory Committee on Immunization Practices (ACIP) a codified federal advisory committee with defined duties, decision rules, and administrative support. It formalizes how ACIP formulates vaccine-use recommendations and how HHS must respond.
The change matters because it shifts several operational practices into law: it creates an explicit evidence standard and publication obligations for departures from ACIP advice, establishes deadlines for considering newly licensed vaccines, ties ACIP’s pediatric vaccine list to the Vaccines for Children program and to coverage policy, and changes the standard for edits to the Vaccine Injury Table used by the National Vaccine Injury Compensation Program (VICP).
At a Glance
What It Does
Creates section 222A in the Public Health Service Act to codify ACIP and require the Committee to produce evidence-based vaccine recommendations. The HHS Director must adopt ACIP recommendations unless they publish an evidence-based justification for rejecting them, and either outcome triggers public posting and congressional notice.
Who It Affects
Directly affects CDC’s National Center for Immunization and Respiratory Diseases, HHS leadership (Director, Secretary, Assistant Secretary for Health), vaccine manufacturers, state and local immunization programs, pediatric providers participating in Vaccines for Children, and health plans tied to federal coverage rules.
Why It Matters
It converts long-standing advisory practice into enforceable procedure, creating predictable paths from licensure to policy (including coverage and VFC purchasing) while imposing rapid transparency and a defined scientific standard for policy divergence and for changes to the VICP’s Vaccine Injury Table.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new statutory home for ACIP inside Title II of the Public Health Service Act and makes chapter 10 of title 5 (federal advisory committee rules) applicable. ACIP’s central mission under the new section is the same as its historical role: review the peer-reviewed evidence and recommend vaccine use to the CDC Director.
What changes is the legal machinery around that advice: recommendations must be grounded in a “preponderance of the best available, peer‑reviewed scientific evidence,” and procedures are spelled out for how recommendations are handled, published, and communicated.
Operationally, the bill requires the Director to review ACIP recommendations and to adopt them unless the Director determines they lack the required evidentiary support and publishes the results of that review. Whether the Director adopts a recommendation or not, the decision carries public transparency obligations: adopted recommendations are posted on HHS’s website and communicated in writing to senior HHS officials; non‑adoptions require a published explanation and a congressional notification within 48 hours.
For newly licensed vaccines (or new indications), ACIP must consider the vaccine at its next regular meeting and issue a recommendation no later than 90 days after a written notice from the license holder; the Committee must also update specified congressional committees on its deliberations.The bill ties ACIP work directly to federal programs. It instructs ACIP to make recommendations used for the preventive services requirement under section 2713 (insurance coverage) and to create and periodically review the pediatric vaccine list and schedules used by the Vaccines for Children program (section 1928 of the Social Security Act).
It also authorizes CDC’s NCIRD to provide management support, designates a full‑time or permanent part‑time Designated Federal Officer with specific meeting and procedural duties, and requires public meetings at least three times per year (and faster consideration timelines after licensure). Membership and governance are detailed: the Comptroller General recommends candidates, the Secretary appoints between 15 and 19 voting members with specified scientific and programmatic expertise, six non‑voting ex‑officio members represent key federal health agencies, and two‑thirds of voting members form a quorum (with mechanisms to temporarily designate ex‑officio voting if needed).Finally, the bill authorizes modest appropriations for operating costs and staff support and amends VICP governance: any removal or other substantive modification of entries on the Vaccine Injury Table must be supported by a preponderance of the best available scientific evidence.
The bill also preserves existing ACIP authorities to avoid narrowing current practice beyond what the text specifies.
The Five Things You Need to Know
The bill requires the HHS Director to adopt ACIP recommendations unless the Director publishes an evidence-based finding that the recommendation is not supported by a preponderance of peer‑reviewed scientific evidence.
If the Director rejects an ACIP recommendation, the Department must publish the basis for that decision and notify the House Energy and Commerce Committee and the Senate HELP Committee within 48 hours.
Upon licensure of a vaccine or new indication, ACIP must consider it at its next regular meeting and must make a recommendation within 90 days after written notification from the vaccine license holder.
ACIP membership is set at 15–19 voting members appointed from candidates recommended by the Comptroller General, plus six named non‑voting ex‑officio federal agency representatives; two‑thirds of voting members constitute a quorum.
The bill amends VICP rules so that removal or other modification of entries on the Vaccine Injury Table must be supported by a preponderance of the best available scientific evidence.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the bill the 'Family Vaccine Protection Act.' This is purely stylistic and establishes how the statute will be cited.
Create statutory ACIP (222A)
Adds a new section to Title II of the Public Health Service Act codifying the Advisory Committee on Immunization Practices. The new text makes federal advisory committee rules (chapter 10 of title 5) applicable, provides for agency support (NCIRD at CDC), authorizes external support from the National Academies, and sets out recordkeeping and public‑access rules. Practically, this anchors ACIP’s existence, structure, and basic administrative support in statute rather than internal agency practice.
Advice, publication, and congressional notification process
Specifies that ACIP must base recommendations on a preponderance of the best available, peer‑reviewed scientific evidence. The Director must either adopt the recommendation—making it an official HHS recommendation and posting it publicly—or publish specific evidence‑based reasons for not adopting it and notify two congressional committees within 48 hours. This provision creates a quick, formalized escalation and transparency path whenever HHS diverges from ACIP advice.
Duties, linkage to federal programs, meetings, and administration
Directs ACIP to produce clinical-use guidance addressing who should receive vaccines, contraindications, recognized adverse events, and special population considerations. It requires ACIP to establish and periodically review the pediatric vaccine list and schedules used by the Vaccines for Children program and to make immunization recommendations that inform the coverage requirement under section 2713. Meetings must be open to the public (with statutory exceptions), held at least three times per year, and follow defined procedural rules under a Designated Federal Officer who handles agendas, approvals, and meeting management.
Membership, quorum, subcommittees, and records
Sets member numbers (15–19 voting members), requires the Comptroller General to recommend candidates with enumerated expertise areas, and lists six non‑voting ex‑officio federal members (HRSA, FDA, CMS, NIH, Indian Health Service, National Vaccine Program Office). Two‑thirds of voting members are a quorum; if quorum is not met because of absences or conflicts, the Designated Federal Officer may temporarily make ex‑officio members voting. Subcommittees may include outside experts but must report to the parent committee and cannot submit advice directly to HHS; records are to be managed under the federal advisory committee records schedule and made publicly accessible subject to FOIA exemptions.
Definitions, funding, and VICP change
Defines 'vaccine' and enumerates 'stakeholder organizations' eligible as liaison representatives by name, authorizes $2.8 million per fiscal year for FY2026–2029 for operating costs, and preserves prior ACIP authorities by rule of construction. Separately, Section 3 amends the VICP statute to require that any removal or substantive modification of the Vaccine Injury Table be supported by a preponderance of the best available scientific evidence — a statutory evidentiary floor for Table changes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Children and families eligible for the Vaccines for Children (VFC) program — the bill gives the pediatric vaccine list statutory weight, which increases predictability for vaccine availability and schedules used in VFC purchasing and administration.
- Clinicians and immunization providers — clearer, statutory pathways from ACIP recommendation to federal guidance and coverage reduce ambiguity about recommended standards of care and help justify clinical decisions and billing.
- Vaccine manufacturers — the 90‑day consideration requirement after notification and the formalized timelines can accelerate the pathway from licensure to public recommendation, improving market predictability.
- State and local public health programs — codified processes, public posting, and congressional reporting increase transparency and help states align vaccine programs and planning with federal recommendations.
Who Bears the Cost
- CDC’s National Center for Immunization and Respiratory Diseases — must provide management, staff, and meeting support and absorb the administrative burden of faster timelines, public postings, and recordkeeping; the authorized funding may not fully cover expanded duties.
- HHS leadership (Director, Secretary) — faces new procedural obligations and compressed windows for producing evidence-based justifications when deviating from ACIP, increasing legal and political exposure and resource needs for rapid reviews.
- Health plans and plan administrators — must update coverage policies promptly when ACIP recommendations are adopted and may face operational costs implementing new preventive services coverage or changes to VFC purchasing lists.
- Vaccine Injury Compensation Program administrators and petitioners — the higher statutory evidentiary floor for modifying the Vaccine Injury Table could complicate or lengthen processes for adding or removing listed injuries, with implications for claims processing.
Key Issues
The Core Tension
The central dilemma is balancing predictability, transparency, and statutory clarity against scientific agility and deliberative independence: binding ACIP processes into law reduces ad‑hoc decisionmaking and makes recommendation outcomes more predictable for programs and industry, but it also risks constraining the Committee’s ability to weigh emerging or incomplete evidence, increases administrative burdens and congressional oversight pressure, and may institutionalize procedural requirements that are ill‑suited to fast‑moving public health emergencies.
The bill creates multiple implementation frictions. First, the evidentiary standard—'a preponderance of the best available, peer‑reviewed scientific evidence'—is a mixture of legal and scientific language that may be difficult to operationalize.
Scientific advisory work typically weighs heterogeneous data, model outputs, and real‑world effectiveness signals; converting that into a single preponderance test risks either forcing premature judgments on limited data or enabling protracted debate over what counts as 'peer‑reviewed' and 'best available.'
Second, the timeline and transparency rules (90‑day recommendation windows after licensure notifications, minimum meeting frequency, and 48‑hour congressional notices for departures) promote speed and accountability but may compress deliberations during early post‑licensure evidence accumulation or in emergency scenarios. Rapid timelines can pressure ACIP and CDC staff to act before longer‑term safety or effectiveness signals materialize.
Third, membership and governance changes—Comptroller General recommendations, a fixed range of voting members, and the ability to temporarily elevate ex‑officio members to voting status—introduce structural levers that could shift the balance of expertise and influence during critical votes. Finally, the modest appropriation authorization may be insufficient to support the new administrative workload (internal reviews, public postings, rapid justifications, and expanded recordkeeping), leaving agencies to reallocate existing resources or slow other activities.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.